Akero Therapeutics: Funding, Investors & Team (Sep 2026)
Akero Therapeutics is dedicated to providing effective treatment options for individuals suffering from serious metabolic disorders like non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage that can lead to severe complications. The company is working on innovative medications that aim to restore metabolic balance and stop the progression of NASH. Their primary clinical program, AKR-001, is a modified FGF21 protein that has the potential to be the leading treatment for NASH. This drug draws from extensive research on FGF21 biology and is designed to target both the liver and fat tissue, reducing liver fat and inflammation while preventing fibrosis.
Akero Therapeutics has raised $743M across 4 funding rounds on record, the most recent an undisclosed round of $319M announced in Mar 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Akero Therapeutics Company Profile and Key Stats
Latest funding round on record: Mar 2024.
Akero Therapeutics Funding Rounds
Akero Therapeutics raised $100M in a Post-IPO Debt announced in Jun 2022.
3 months later, a Post-IPO Equity of $200M was announced in Sep 2022.
8 months later, an undisclosed round of $124M was announced in May 2023.
10 months later, an undisclosed round of $319M was announced in Mar 2024.
Akero Therapeutics Founders and Leadership Team
Contact details for the Akero Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Akero Therapeutics Funding Compared to Other Biotechnology Startups
Akero Therapeutics' latest round of $319M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Akero Therapeutics in Biotechnology and Cambridge
Companies Similar to Akero Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Akero Therapeutics Funding FAQs
What does Akero Therapeutics do?
Akero Therapeutics is dedicated to providing effective treatment options for individuals suffering from serious metabolic disorders like non-alcoholic steatohepatitis (NASH), a condition characterized by liver inflammation and damage that can lead to severe complications. The company is working on innovative medications that aim to restore metabolic balance and stop the progression of NASH. Their primary clinical program, AKR-001, is a modified FGF21 protein that has the potential to be the leading treatment for NASH. This drug draws from extensive research on FGF21 biology and is designed to target both the liver and fat tissue, reducing liver fat and inflammation while preventing fibrosis.
How much funding has Akero Therapeutics raised?
Akero Therapeutics has raised $743M across 4 rounds on record. The most recent is an undisclosed round of $319M announced in Mar 2024.
When did Akero Therapeutics last raise funding?
Akero Therapeutics' most recent funding round on record is an undisclosed round of $319M, announced in Mar 2024.
Who founded Akero Therapeutics?
FundedIQ lists Tim Rolph (Founder) at Akero Therapeutics.
Where is Akero Therapeutics headquartered?
Akero Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Akero Therapeutics have?
Akero Therapeutics is in the 11-50 employee band.
How does Akero Therapeutics' funding compare to other Biotechnology startups?
Akero Therapeutics' latest round of $319M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Akero Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Akero Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.